)
Absci (ABSI) investor relations material
Absci Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
ABS-201 HEADLINE is progressing in Phase 1/2a for pattern hair loss; interim 13-week proof-of-concept data are expected in December 2026 and full 26-week data in early 2027.
A Phase 2 STORYLINE trial for endometriosis is planned for mid-2027; ABS-202 remains in nonclinical development.
Origin-1 generative design paired with lab-in-the-loop validation; the first two programs reached IND or foreign equivalent in ~2 years at ~$15M per program, versus cited industry averages of 4–6 years and >$50M.
Financial highlights
Q3 partner program revenue was $0.304M vs. $0.378M YoY; net loss was $33.3M vs. $28.7M.
Q3 R&D expense was $23.6M vs. $19.2M, mainly reflecting ABS-201 development; SG&A was $9.0M vs. $8.4M, primarily due to stock-based compensation.
9M revenue was $0.837M vs. $2.150M and net loss was $96.1M vs. $85.6M.
9M R&D expense rose 17% to $65.5M; operating expenses increased 10% to $100.8M, including SG&A of $27.3M and D&A of $8.1M.
Q3 diluted loss per share was $0.19 vs. $0.20; 9M diluted loss per share was $0.60 vs. $0.65.
Outlook and guidance
Interim 13-week HEADLINE data are expected in December 2026, including all 300 mg participants, most 600 mg participants and potentially an initial look at 1,200 mg; full 26-week data are expected in early 2027.
The 26-week results will inform Phase 3 dose selection; the 13-week interim is directional and not intended to change trial conduct.
STORYLINE is planned for mid-2027, subject to protocol finalization and regulatory clearance; planned enrollment is ~150 patients across ~10 or more countries.
Cash, cash equivalents and marketable securities of $173.7M are projected to fund operating plans into H2 2028.
R&D expense is expected to rise as HEADLINE, later-stage PHL trials, STORYLINE, other internal programs and platform investment advance.
- ABS-201 advances toward pattern hair loss proof of concept as AI design capabilities expand.ABSI
Corporate presentation - ABS-201 readouts are approaching, with cash runway into H2 2028.ABSI
3rd Annual Guggenheim Healthcare Innovation Conference - ABS-201 advances with strong safety, high demand, and pivotal data expected in December.ABSI
Morgan Stanley 24th Annual Global Healthcare Conference - AI-driven clinical programs advance toward key milestones, supported by robust cash reserves.ABSI
H.C. Wainwright 28th Annual Global Investment Conference - AI-driven antibody platform advances novel therapies for hair loss and endometriosis, targeting large markets.ABSI
Corporate presentation - Positive interim data and strong cash reserves support continued clinical and pipeline progress.ABSI
Q2 2026 - AI-powered drug discovery advances key assets toward pivotal clinical milestones and partnerships.ABSI
Morgan Stanley 23rd Annual Global Healthcare Conference - AI-driven antibody platform advances ABS-101 and ABS-201 toward major clinical milestones.ABSI
R&D Day 2024 - Generative AI-driven antibody design, AMD partnership, and pipeline milestones set stage for 2025.ABSI
43rd Annual J.P. Morgan Healthcare Conference 2025
Next Absci earnings date
Next Absci earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)